Published in final edited form as:

Psychooncology. 2014 January ; 23(1): 40–51. doi:10.1002/pon.3372.

Comorbidity of common mental disorders with cancer and their treatment gap: Findings from the World Mental Health Surveys

Ora Nakash¹, Itzhak Levav², Sergio Aguilar-Gaxiola³, Jordi Alonso⁴, Laura Helena Andrade⁵, Matthias C. Angermeyer⁶, Ronny Bruffaerts⁷, Jose Miguel Caldas-de-Almeida⁸, Slivia Florescu⁹, Giovanni de Girolamo¹⁰, Oye Gureje¹¹, Yanling He¹², Chiyi Hu¹³, Peter de Jonge¹⁴, Elie G. Karam¹⁵, Viviane Kovess-Masfety¹⁶, Maria Elena Medina-Mora¹⁷, Jacek Moskalewicz¹⁸, Sam Murphy¹⁹, Yosikazu Nakamura²⁰, Marina Piazza²¹, Jose Posada-Villa²², Dan J. Stein²³, Nezar Ismet Taib²⁴, Zahari Zarkov²⁵, Ronald C. Kessler²⁶, and Kate M. Scott²⁷

¹School of Psychology, Interdisciplinary Center (IDC), Herzliya, Israel ²Department of Community Mental Health, Faculty of Social Welfare & Health Sciences, Haifa University, Haifa, Israel

³Center for Reducing Health Disparities (CRHD), Community Engagement Program of the Clinical Translational Science Center (CTSC), University of California, Davis, School of Medicine, Sacramento, CA, US ⁴IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Pompeu Fabra University (UPF), Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain ⁵Institute of Psychiatry University of São Paulo Medical School, São Paulo, Brazil ⁶Center for Public Mental Health, Gosing am Wagram, Austria ⁷Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Leuven, Belgium ⁸Chronic Diseases Research Center (CEDOC) and Department of Mental Health, Faculdade de Ciências Médicas Universidade Nova de Lisboa Lisbon, Portugal ⁹Scoala Nationala de Sanatate Publica, Management si Perfectionare in Domeniul Sanitar (SNSMPDSD), Bucharest, Romania ¹⁰IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy ¹¹Department of Psychiatry, University College Hospital, Ibadan, Nigeria ¹²Shanghai Mental Health Center, Shanghai, PR China ¹³Shenzhen Institute of Mental Health and Shenzhen Kangning Hospital, Guangdong Province, PR China ¹⁴University Medical Center Groningen, Groningen, The Netherlands ¹⁵Institute for Development, Research, Advocacy & Applied Care (IDRAAC) Medical Institute for Neuropsychological Disorders (MIND); Department of Psychiatry & Clinical Psychology St. George Hospital University Medical Center Balamand University, Faculty of Medicine Beirut, Lebanon ¹⁶Department of Epidemiology and Biostatistics, Paris Descartes University research Unit EHESP School for Public Health, Paris, France ¹⁷Instituto Nacional de Psiquiatria Ramon de la Fuente, Mexico City, Mexico ¹⁸Institute of Psychiatry and Neurology, Warsaw, Poland

Address for correspondence: Ora Nakash, School of Psychology, Interdisciplinary Center (IDC) Herzliya, P.O.Box 167, Herzliya, 46150, Israel. onakash@idc.ac.il; Tel.: 972-9-9527946; Fax: 972-9-9602845.

Author Contributions: Drs. Nakash, Levav and Scott take full responsibility for the integrity of the data analysis and accuracy of results reported. All authors had full access to all the data in the study. The final manuscript has been seen and approved by all authors.

Conflict of Interest: No other conflict of interest exists.

Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or U.S. Government.

¹⁹University of Ulster, Londonderry, UK ²⁰Jichi Medical University, Shimotsuke, Tochigi, Japan ²¹Universidad Peruana Cayetano Heredia, Lima, Peru ²²Universidad Colegio Mayor de Cundinamarca, Bogota, Colombia ²³Department of Psychiatry, University of Cape Town, South Africa ²⁴Mental Health Center-Duhok, Kurdistan Region, Iraq ²⁵National Center of Public Health and Analyses, Department of Mental Health, Sofia, Bulgaria ²⁶Department of Health Care Policy, Harvard Medical School, Boston, MA, USA ²⁷Department of Psychological Medicine, Otago University, Dunedin, New Zealand

Abstract

Objective—To study the comorbidity of common mental disorders (CMDs) and cancer, and the mental health treatment gap among community residents with active cancer, cancer survivors and cancer-free respondents in 13 high- and 11 low-middle income countries.

Methods—Data were derived from the World Mental Health Surveys (N=66,387; n=357 active cancer, n=1,373 cancer survivors, n=64,657 cancer free respondents). The WHO/Composite International Diagnostic Interview was used in all surveys to estimate CMDs prevalence rates. Respondents were also asked about mental health service utilization in the preceding 12 months. Cancer status was ascertained by self-report of physician's diagnosis.

Results—Twelve month prevalence rates of CMDs were higher among active cancer (18.4% SE=2.1) than cancer free respondents (13.3%, SE=0.2) adjusted for socio-demographic confounders and other lifetime chronic conditions (Adjusted Odds Ratio (AOR)=1.44 95% CI 1.05–1.97). CMD rates among cancer survivors (14.6% SE=0.9) compared with cancer-free respondents did not differ significantly (AOR=0.95 95% CI 0.82–1.11). Similar patterns characterized high and low-middle income countries. Of respondents with active cancer who had CMD in the preceding 12 months 59% sought services for mental health problems (SE=5.3). The pattern of service utilization among people with CMDs by cancer status (highest among persons with active cancer, lower among survivors and lowest among cancer-free respondents) was similar in high- (64.0% SE=6.0, 41.2% SE=3.0, 35.6% SE=0.6) and low-middle income countries (46.4% SE=11.0, 22.5% SE=9.1, 17.4% SE=0.7).

Conclusions—Community respondents with active cancer have relatively higher CMD rates and relatively high treatment gap. Comprehensive cancer care should consider both factors.

Keywords

Cancer; Epidemiology; Mental health; Oncology; Treatment gap; World Mental Health Surveys

Introduction

Cancer is a leading cause of death. It accounted for eight million deaths worldwide (around 15% of all deaths) in 2010 (38% more than in 1990) [1]. According to the World Bank classification of countries by income, rates for all cancers combined (excluding non-melanoma skin cancers) rise as the country income rises. The age-adjusted incidence rate in high income countries in 2008 was 255.8 per 100,000 population for all cancers combined, compared with the rate in low-middle income countries, 146.8 per 100,000 population [2]

A significant proportion of persons with cancer at different stages of the disease trajectory develop mental disorders, primarily affective and anxiety disorders (henceforth, common mental disorders) [3–8]. In this paper we examined the comorbidity of common mental disorders and cancer and their respective mental health treatment gap (i.e., the proportion of individuals with active cancer and a mental disorder who have received no treatment for their mental disorder). Also, we explored the universality of the findings by looking at data in countries with contrasting income levels.

Comorbidity of cancer and mental disorders

Recent meta-analyses showed that approximately one-third of persons with cancer in acute care hospitals are affected by common mental disorders [5, 9]. Of these, depression has been the one most studied [9, 10, 11]. Although more limited, epidemiological studies using diagnostic instruments also found associations between cancer and increased rates of major depression and anxiety disorders [10].

Psychiatric morbidity post-cancer onset increases in direct association with the level of disability, advanced illness and pain [3, 5], following, e.g., the biological effects of the malignancy, side effects of certain chemotherapeutic drugs, grief about current and anticipated losses, mutilation, and fear of death [11]. Accordingly, timely and accurate diagnosis and appropriate treatment of comorbid mental disorders is required in an effort not only to increase quality of life but also to reduce adverse effects on cancer course, length of hospital stay, treatment adherence and efficacy, and possibly prognosis and survival [12–17].

Treatment for common mental disorders among persons with cancer

The research evidence on both the success and limitations of psychological and pharmacological treatments for common mental disorders is mounting [18]. The National Institute of Health and Clinical Excellence (NICE) has published intervention guidelines for these disorders [19], and so has the World Health Organization (WHO), with the main focus on primary care practitioners (cf. the Mental Health Gap Action Program, that also made available in its website the effect sizes of recommended interventions [20]).

Importantly for our inquiry, psycho-oncological research in recent decades has documented the efficacy of interventions for common mental disorders among persons with cancer [21–23]. For example, Li et al., [24], following a comprehensive review, suggested that both psychosocial and pharmacological interventions can alleviate depression in persons with cancer. Although further research is needed to overcome lingering limitations [24], the US Institute of Medicine did recommend in its 2008 report *Cancer care for the whole patient* [12] that appropriate integrated psychosocial services should be provided.

Treatment gap in mental health care among persons with cancer

The difference between true and the treated prevalence rates for psychiatric disorders is generally substantial [25, 26]. It exceeds 50% worldwide, and it approaches 90% in the least resourced countries for common mental disorders [27–31]. A WHO review of 37 studies worldwide estimated that the treatment gap for major depression and dysthymia reached

56%, and for generalized anxiety disorder, 58% [26]. In the World Mental Health Surveys (WMHS), the largest international psychiatric epidemiological study ever conducted, Wang et al. [25] documented the gaps in the mental health service-delivery for common mental disorders in 17 countries. Their findings showed that at least two-thirds of the roughly 30% of the population worldwide expected to have common mental disorders every year [32] do not receive any treatment in the countries studied [see also 27].

Psycho-oncological research has shown similar treatment gaps for mental disorders among persons with cancer [8, 12, 13, 33]. For example, a US community-based study found that only 35% of cancer survivors who reported mental problems accessed specialized services [34]. In another US study conducted among persons with cancer in a public hospital, barely 12% of those diagnosed with depression received antidepressant medications, and even fewer (5%) accessed a mental health counselor [35]. The frequent failed recognition of mental problems due to objective barriers, e.g., availability and accessibility of services [13, 16, 36], and subjective factors, e.g. stigma [37, 38], may lead to the treatment gap.

The WMHS provides a unique opportunity to assess the comorbidity of common mental disorders and the respective treatment gap in individuals with cancer residing in the community in a multiplicity of countries. As mentioned above, to overcome existing limitations in the literature, WMHS relied on a large sample size and used uniform and well-tested methods of case ascertainment and diagnosis of mental disorders. The data jointly collected in 24 countries provide the case for action for both advocacy efforts and program and service planning.

Objectives

We investigated: 1) the 12-month prevalence of comorbid common mental disorders in persons with active and past cancer, in all countries combined and in countries grouped by country income level; 2) the associations between 12-month prevalence rates of common mental disorders and lifetime cancer, with adjustment for key covariates; and 3) the prevalence rate of mental health service use in the preceding 12 months among those with a common 12-month mental disorder, comparing those with active cancer to cancer survivors, to individuals with no cancer history, and to individuals with other chronic physical conditions. Data were drawn from the WMHS conducted in 24 high income- and low-middle income countries.

Methods

Survey samples and procedures

The World Mental Health Surveys are psychiatric epidemiologic studies of community-dwelling adults in Africa, the Americas, Asia, Europe, the Middle East and the Pacific conducted between the years 2001–2011. Survey procedures followed similar guidelines in all sites, and they were planned and coordinated by a team of researchers from the University of Michigan, Harvard Medical School, and the World Health Organization (see details in [39]).

Data from all of the WMH Surveys that had collected the requisite data on cancer status were included in this report. The surveys included in this study came from 13 countries classified by the World Bank as high income (Belgium, France, Germany, Israel, Italy, Japan, New Zealand, Northern Ireland, Portugal, Poland, Spain, The Netherlands, and USA), and 11 countries classified as low-middle income (Brazil, Bulgaria, Colombia, Iraq, Lebanon, Mexico, Nigeria, People's Republic of China -the survey included two sites-, Peru, Romania, and South Africa). Most surveys were based on stratified multi-stage, clustered area probability household samples and all were conducted face-to-face by trained lay interviewers. Response rates ranged from 45.9% in France to 95.2% in Iraq, with a weighted average response rate of 79.9%. Two countries (Colombia and Mexico) selected representative urban areas, one selected states (Nigeria) and four selected metropolitan areas (Brazil, India, Japan, People's Republic of China).

Interview schedules

Section I included the core diagnostic assessment of mental disorders (see below), while in Section II additional information was collected regarding a wide range of survey aims, including self-reports on cancer (see below), and other chronic physical conditions (e.g., diabetes, epilepsy, HIV). All respondents completed Section I, and those who met criteria for any mental disorder in addition to a probability sample of remaining respondents were administered Section II. Service utilization items (see below) were asked from all respondents. The proportion of respondents that completed Section II was weighted by the inverse of the probability of the selection to adjust for differential sampling. Additional weights were used to adjust for differential probabilities of selection within households, for non-response and to match the samples to population socio-demographic distributions. The analyses presented in this paper used the Section II subsample (N=66,387).

The central WMHS staff trained bilingual supervisors in each country. A WHO protocol was used to translate instruments and training materials [39]. Some surveys were carried out in more than one language, while in others the country's single official language was utilized. Quality control protocols were standardized across countries to check for interviewer accuracy and to specify data cleaning and coding procedures. Each country obtained approval by IRB or ethics committees, including for informed consent and the protection of human rights (for further details on methods see [39]).

Measures

Psychiatric diagnostic assessment—All surveys used the WMHS version of the WHO Composite International Diagnostic Interview (CIDI 3.0) [40]. The CIDI is a fully-structured lay-administered interview which ascertains lifetime prevalence of disorders (disorder occurring at any age up to the time of the interview) as well as recent episodes or symptoms, allowing estimation of 12-month prevalence rates. Disorders were assessed using the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (*DSM-IV* [41]). In the current study we focused on anxiety disorders (panic disorder, generalized anxiety disorder, agoraphobia without panic, post-traumatic stress disorder, social phobia, specific phobia, obsessive-compulsive disorder) and mood disorders (major depressive disorder and dysthymia). Organic exclusion criteria were taken into account in

determining *DSM-IV* diagnoses. CIDI showed high test-retest reliability [42], and the WMHS clinical reappraisal studies showed good CIDI-Structured Clinical Interview for *DSM-IV* (SCID) agreement, and provided support for the construct validity of the interview [43].

Cancer and other chronic physical conditions—These were assessed using a checklist adapted from the US Health Interview Schedule [43]. Respondents were asked whether a physician or any other health professional ever told them they have cancer. Participants who answered positively were further asked to indicate cancer site and whether they were currently in “active treatment for your cancer”, “in remission” or “cured”. As in past research [8], the latter two groups were combined (“cancer survivors”).

Respondents were also asked whether a doctor or any other health professional ever told them they had one or more of the following conditions: arthritis, back and neck pain, frequent or severe headaches, heart disease, high blood pressure, asthma, diabetes, peptic ulcer, other chronic lung diseases, stroke, other chronic pain, epilepsy and HIV. For conditions that could have remitted, respondents were asked whether the condition was present at the time of the interview. Methodological research has shown that such checklists provide useful information about treated or currently undetected chronic conditions [44], and that they predict outpatient health care use, hospitalization and mortality [45]. Self-report of chronic physical conditions shows moderate to high agreement with medical records data [46].

Mental health service utilization—All respondents were asked whether they had ever visited, and specifically within the past 12 months, any one of a list of the following agents from different sectors for problems with emotions or mental health as follows: mental health sector (psychiatrist, psychologist, social worker and counselor in mental health); general medical sector (general practitioner, other physician, nurse, occupational therapist or any healthcare professional); human services sector (religious or spiritual advisor or social worker or counselor in any setting other than a specialty mental health setting); complementary and alternative medicine sector (any other type of healer, such as herbalist or homeopath, participation in an internet support group, or in a self-help group) [43].

Statistical analysis

All cancer sites were aggregated to increase statistical power. Prevalence estimates of mental disorders comparing “active cancer”, “cancer survivors” and “cancer free” respondents were derived using cross-tabulations. Logistic regression models were used to calculate associations (odds ratios (ORs) and 95% confidence intervals (95% CI)) between cancer status and mental disorders. These models accounted for the potential confounding effects of socio-demographic factors and other lifetime chronic health conditions. As the WMH data are both clustered and weighted, the design-based Taylor series linearization [47] implemented in version 10 of the SUDAAN software system [48] was used to estimate standard errors and evaluate the statistical significance of coefficients.

Results

Sample characteristics

Several demographic characteristics differed significantly by cancer status across participating countries (Table 1). Respondents with active cancer and cancer survivors were older, had fewer years of formal education and were more likely to be currently or previously married than cancer-free respondents. A higher percentage of women than men reported they had active cancer or were cancer survivors. In addition, a higher percentage of respondents with active cancer and cancer survivors had one or more chronic physical condition/s compared with cancer-free respondents.

The reported rates of cancer were higher in high income countries compared with low-middle income countries (Table 2).

Psychiatric morbidity

Twelve-month rates of common mental disorders were higher among respondents with active cancer (18.4% SE=2.1) than among cancer survivors (14.6% SE=0.9) and cancer-free respondents (13.3%, SE=0.2) in all countries combined (Table 3). A similar pattern emerged in separate analyses of high and low-middle income countries (Table 3).

Having active cancer, relative to being cancer-free was significantly associated with mood disorders after adjustment for age, gender and country income group (OR= 1.81 95% CI 1.26–2.61). There was no such significant association between being a cancer survivor and mood disorders. The association between active cancer and mood disorders was unaffected by adjustment for socio-demographic variables (education and marital status), and was reduced, but remained significant, after adjustment for comorbid lifetime physical conditions (OR= 1.69 95% CI 1.15–2.48). The same pattern, albeit of somewhat lesser magnitude, was evident for associations between active cancer and anxiety disorders (Table 4).

Mental health service utilization

Of all respondents across participating countries with active cancer and CMDs in the preceding 12 months, 59% reported seeking services for mental health problems (SE=5.3). Most frequently they consulted general physicians (37.9% SE=6.0) and/or mental health specialists (29.9% SE=5.4). This service utilization pattern was higher than those reported by cancer survivors (39.1% SE=2.9) and cancer-free respondents (27.7% SE=0.5). The reported higher mental health service utilization among persons with active cancer compared with survivors and cancer-free respondents was consistent across all types of services (i.e., mental health specialty, general medical, human services, and complementary and alternative medicine) (Table 5).

Although the treatment gap was present in both high- and low-middle income countries, mental health service utilization was higher in the former than in the latter group. The pattern of service utilization by cancer status was similar: higher among persons with active cancer compared with cancer survivors and cancer-free respondents across both high (64.0%

SE=6.0, 41.2% SE=3.0, 35.6% SE=0.6, respectively) and low-middle income countries (46.4% SE=11.0, 22.5% SE=9.1, 17.4% SE=0.7, respectively) (Table 5). The most frequently reported service sector sought by respondents in high income countries was the general physician (43.6% SE=6.7), while in low-middle income countries it was the mental health specialty sector (35.4% SE=11.9) (Table 5). However, due to the small cell sizes for those with cancer in low-middle income countries in this analysis, these patterns require further confirmation.

Discussion

This epidemiological study examined the prevalence of common mental disorders and mental health related service utilization patterns among community respondents with active cancer and cancer survivors compared to people who informed that they were cancer-free. The study advances the existing literature by virtue of being conducted in large community-based population samples, using similar research methods and procedures and relying on valid and reliable diagnostic measures of mood and anxiety disorders. The fact that the study was conducted in countries of contrasting income level allowed an investigation of the consistency of findings.

The results showed elevated risk of comorbid common mental health disorders among persons who at the time of the study were undergoing treatment for cancer across all countries studied compared with either cancer survivors or cancer-free respondents. Our findings thus confirm the results of the few prior community-based studies that found high rates of comorbid mental disorders among people with active cancer [8, 10]. Notably, the comorbidity rates were lower in our study than in a previous study conducted in the US, the National Comorbidity Survey (NCS) [10], likely due to the fact that the current study included respondents spanning the full adult age range (compared to a restricted age range of 15–54 in the NCS) and from a wide range of countries. This underlies the universality of these findings. Our findings further showed that cancer survivors did not differ from cancer-free respondents in the prevalence rates of common mental disorders, a likely proxy measure of eventual psychological adjustment.

Because these are cross-sectional data, the question whether the common mental disorders associated with active cancer in this study preceded or resulted from the cancer diagnosis remains open. Past research has documented that the psychiatric morbidity post-cancer onset increases in direct association with the level of disability, advanced illness and pain [3, 5]. Further research is needed to clarify the timing of the mental disorders. However, the fact that we found that the 12-month mental disorders were elevated among those with active cancer but not among cancer survivors, may suggest that they developed after the cancer diagnosis. They may further suggest that common mental disorders among persons with cancer represent an adjustment problem to the illness and that these comorbid disorders are less etiologically intertwined [see also 49, 50]. This hypothesis is supported by research documenting that cancer survivors compared with respondents with no cancer history show resilience in important domains of psychosocial adjustment such as social well-being, spirituality and personal growth [51].

Whether the comorbid mental disorders preceded or followed cancer onset, our findings show that the treatment gap for mental health problems among persons with cancer is frequent and universal, and it appears to be more pronounced in low-middle income countries compared with high income countries. The treatment gap among individuals with cancer is consistent with findings based on the general population [25]. Although the treatment gap among persons with cancer is substantial (59% of persons with active cancer and comorbid mental disorder accessed treatment across all countries), it is lower than the one observed for other chronic conditions (i.e., only 32% of respective respondents accessed care), and or the general population (approximately 27% of respective respondents accessed care). It is thus, plausible to state that access to care for mental health disorders is improved among persons with cancer compared with the general population. In this regard, we observed a pattern such that respondents in low-middle income countries sought services from mental health specialists, whereas their counterparts in high income countries sought services more frequently from general physicians, although specialized services are more available in the latter group. However, as noted earlier, the small sample size of those with cancer in lower income countries in this study means that these patterns can only be taken as suggestive.

Importantly, access to care examined in the current paper does not guarantee appropriateness and quality of services. Thus, continued efforts should be directed to closing the treatment gap alongside improving correct identification of need (without over- or under-diagnosis) and the quality of services [52].

This study has several limitations. First, as cancer status was ascertained through self-report some misclassification may have occurred. Notably, however, self-report of chronic physical conditions shows moderate to high agreement with medical records data [46]. Second, due to statistical power constraints analyses were performed on aggregate types of cancer and across genders and national groups. These may have concealed differences. Third, no information was available on cancer stage, which may have an effect on the association with the mental health-related variables. Fourth, sampling strategies varied somewhat among countries, with some including samples that were not nationally representative. These and other factors, such as country differences in identification of cancer and transmission of information to the respondents, differences in treatment and odds of survival, and uneven respondents' readiness to disclose the existence of an illness that still carries stigma, may account for some of the differences in the cancer rates among the countries included in our study. Yet, with regard to the last point, the cancer rates in our study compared with the WHO data on cancer morbidity and mortality [49] showed minimal differences (for countries where data on morbidity exists, the rank order of countries was identical or differed by one place for Israel, Italy, New Zealand, Poland, Romania and South-Africa, and differed by 2–3 places for Belgium, Bulgaria, Germany, Netherlands, Portugal, Spain, and the US [53]). It is thus plausible to assume that our results ultimately reflect a conservative estimation of both the prevalence and treatment gap rates, particularly in low-middle income countries [29, 54], since those respondents who answered the question about cancer "negatively" and were identified as "cancer free" may have indeed been "cancer -active" or "cancer survivors". Overall, in our opinion, the study strengths noted earlier in the discussion balance the limitations.

Conclusion

The findings raise an important case for action both by acting collectively and by single country efforts. This is particularly important given that the literature indicates both the existence of effective treatments [24] and the adverse impact of the comorbid mental disorders on quality of life [55], adherence with recommended care, increased health-care costs [56] and, possibly, reduced survival [22, 57, 58].

Our findings regarding the prevalence of common mental disorders and mental health treatment gap are overall consistent across countries of contrasting income level, highlighting the universality of the importance of bridging the treatment gap. Mental health treatment gap is a public health problem that stubbornly remains in general and for highly vulnerable populations, and this despite the existence of proven interventions for anxiety and depressive disorders, e.g., psychopharmacological [59] and psychotherapeutic (e.g., cognitive-behavioral therapy [19]) interventions.

Actions to bridge the gap through improved availability and accessibility of the services and the reduction of the subjective barriers such as stigma, would facilitate access to the benefits derived from evidence-based mental health treatments in both primary care and/or in specialized services [22, 60]. Also, for a more complete remedy of the situation, specific training should be made available for the medical staff in identifying and treating the comorbid mental disorders [33], and wherever possible, to include specialized mental health providers as an integral part of the multidisciplinary team caring for person with cancer.

Acknowledgments

Dr. Kessler has been a consultant for AstraZeneca, Analysis Group, Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly & Company, GlaxoSmithKline Inc., HealthCore Inc., Health Dialog, Hoffman-LaRoche, Inc., Integrated Benefits Institute, John Snow Inc., Kaiser Permanente, Matria Inc., Mensante, Merck & Co, Inc., Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc., Primary Care Network, Research Triangle Institute, Sanofi-Aventis Groupe, Shire US Inc., SRA International, Inc., Takeda Global Research & Development, Transcept Pharmaceuticals Inc., and Wyeth-Ayerst. Dr. Kessler has served on advisory boards for Appliance Computing II, Eli Lilly & Company, Mindsite, Ortho-McNeil Janssen Scientific Affairs, Johnson & Johnson, Plus One Health Management and Wyeth-Ayerst. Dr. Kessler has had research support for his epidemiological studies from Analysis Group Inc., Bristol-Myers Squibb, Eli Lilly & Company, EPI-Q, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs., Pfizer Inc., Sanofi-Aventis Groupe, Shire US, Inc., and Walgreens Co. Dr. Kessler owns 25% share in DataStat, Inc. Dr. Stein has received research grants and/or consultancy honoraria from Abbott, Astra Zeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth.

Funding/Support: The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Colombian National Study of Mental Health (NSMH) was supported by the Ministry of Social Protection, with supplemental support from the Saldarriaga Concha Foundation. The European surveys were funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123; EAHF 20081308), the Piedmont Region (Italy), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline.

Implementation of the Iraq Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey was supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health / Fogarty International Center (R03 TW006481-01), Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from AstraZeneca, Eli Lilly, GlaxoSmithKline, Hikma Pharm, Pfizer, Roche, Sanofi-Aventis, Servier and Novartis. The Mexican National Comorbidity Survey (MNCS) was supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology, and Information. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Polish project *Epidemiology of Mental Health and Access to Care – EZOP Poland* was carried out by the Institute of Psychiatry and Neurology in Warsaw in consortium with Department of Psychiatry - Medical University in Wroclaw and National Institute of Public Health-National Institute of Hygiene in Warsaw and in partnership with Psykiatrist Institut Vinderen – Universitet, Oslo. The project was funded by the Norwegian Financial Mechanism and the European Economic Area Mechanism as well as Polish Ministry of Health. No support from pharmaceutical industry neither other commercial sources was received. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health, present National School of Public Health Management & Professional Development, Bucharest), with technical support of Metro Media Transilvania, the National Institute of Statistics – National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The South Africa Stress and Health Study (SASH) is supported by the US National Institute of Mental Health (R01-MH059575) and National Institute of Drug Abuse with supplemental funding from the South African Department of Health and the University of Michigan. The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust.

Additional Funding: Work on this paper was funded by a grant from the Health Research Council of New Zealand to Kate M Scott.

Role of the Sponsors: The sponsors had no input into the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review or approval of the manuscript.

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*. 2013; 380:2095–2128.
2. World Health Organization. [Accessed December 2 2012] GLOBOCAN 2008. 2008. Available at <http://globocan.iarc.fr/>
3. Meyerowitz, BE.; Oh, S. Book Handbook of behavioral science and cancer: Psychosocial response to cancer diagnosis and treatment. Washington DC: American Psychological Association; 2009.
4. Miovic M, Block S. Psychiatric disorders in advanced cancer. *Cancer*. 2007; 110:1665–1676. [PubMed: 17847017]

5. Singer S, Das-Munshi J, Brahler E. Prevalence of mental health conditions in cancer patients in acute care—a meta-analysis. *Ann Oncol*. 2010; 21:925–930. [PubMed: 19887467]
6. Arden Close E, Gidron Y, Moss Morris R. Psychological distress and its correlates in ovarian cancer: A systematic review. *Psycho-Oncology*. 2008; 17:1061–1072. [PubMed: 18561287]
7. Kadan Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG. Psychiatric disorders and mental health service use in patients with advanced cancer. *Cancer*. 2005; 104:2872–2881. [PubMed: 16284994]
8. Nakash O, Shemesh A, Nagar M, Levav I. Cancer and common mental disorders in the community: Results of the Israel-World Mental Health Survey. *Eur J Psychiat*. 2012; 26:174–184.
9. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. *Lancet*. 2011; 12:160–174.
10. Honda K, Goodwin RD. Cancer and mental disorders in a national community sample: Findings from the National Comorbidity Survey. *Psychother Psychosom*. 2004; 73:235–242. [PubMed: 15184718]
11. Massie MJ. Prevalence of depression in patients with cancer. *Natl Cancer I Monogr*. 2004; 32:57–71.
12. Institute of Medicine. Cancer care for the whole patient: Meeting the psychosocial health needs. Washington DC: 2008.
13. Levav I. The treatment gap of depression in persons with cancer. *Asian Pac J Cancer P*. 2010; 11:117–119.
14. Sollner W, DeVries A, Steixner E, Lukas P, Sprinzi G, Rumpold G, et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling? *Brit J Cancer*. 2001; 84:179–185. [PubMed: 11161373]
15. Jacobsen PB, Wagner LI. A new quality standard: The integration of psychosocial care into routine cancer care. *J Clin Oncol*. 2012; 30:1154–1159. [PubMed: 22412134]
16. Carlson LE, Waller A, Mitchell AJ. Screening for distress and unmet needs in patients with cancer: Review and recommendations. *J Clin Oncol*. 2012; 30:1160–1177. [PubMed: 22412146]
17. Stommel M, Given BA, Given CW. Depression and functional status as predictors of death among cancer patients. *Cancer*. 2002; 94:2719–2727. [PubMed: 12173342]
18. National institute of health and clinical excellence (NICE). Depression: Management of depression in primary and secondary care. NICE guidelines. 2009 Available at <http://www.nice.org.uk/Search.do?keywords=depression&newSearch=true&searchType=Guidance>.
19. National institute of health and clinical excellence (NICE). NICE guidelines. 2012 Available at www.nice.org.uk/aboutguidance.
20. World Health Organization. [Accessed December 10 2012] mhGap Evidence Resource Center. 2012. Available at http://www.who.int/mental_health/mhgap/evidence/en/index.html
21. Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. *J Clin Oncol*. 2011; 29:413–420. [PubMed: 21149651]
22. Spiegel D. Mind matters in cancer survival. *JAMA*. 2011; 305:502–503. [PubMed: 21285429]
23. Fawzy FI, Fawzy NW, Arndt LA, Pasnau RO. Critical review of psychosocial interventions in cancer care. *Arch Gen Psychiat*. 1995; 52:100. [PubMed: 7848046]
24. Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. *J Clin Oncol*. 2012; 30:1187–1196. [PubMed: 22412144]
25. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al. Worldwide use of mental health services for anxiety, mood, and substance disorders: results from 17 countries in the WHO World Mental Health (WMH) Surveys. *Lancet*. 2007; 370:841. [PubMed: 17826169]
26. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. *B World Health Organ*. 2004; 82:858–866.
27. Patel V, Maj M, Flisher AJ, De Silva MJ, Koschorle M, Prince M, et al. Reducing the treatment gap for mental disorders: a WPA survey. *World Psychiatry*. 2010; 9:169. [PubMed: 20975864]

28. Eaton J, McCay L, Semrau M, Chatterjee S, Baingana F, Araya R, et al. Scale up of services for mental health in low-income and middle-income countries. *Lancet*. 2011
29. Saxena S, Thornicroft G, Knapp M, Whiteford H. Global Mental Health 2-Resources for mental health: scarcity, inequity, and inefficiency. *Lancet*. 2007; 370:878–890. [PubMed: 17804062]
30. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. *JAMA*. 2004; 291:2581–2590. [PubMed: 15173149]
31. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. *Eur Neuropsychopharm*. 2005; 15:357–376.
32. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. *New Eng J Med*. 2005; 352:2515–2523. [PubMed: 15958807]
33. Nakash O, Nagar M, Mandel R, Alon S, Gottfried M, Levav I. Ethnic differentials in mental health needs and service utilization among persons with cancer. *Support Care Cancer*. 2012; 20:2217–2221. [PubMed: 22562585]
34. Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: Analyses of the National Health Interview Survey. *J Clin Oncol*. 2002; 20:4581–4590. [PubMed: 12454116]
35. Ell K, Sanchez K, Vourlekis B, Lee PJ, Dwight-Johnson M, Lagomasino I, et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. *J Clin Oncol*. 2005; 23:3052–3060. [PubMed: 15860863]
36. Greenberg DB. Barriers to the treatment of depression in cancer patients. *Natl Cancer I Monogr*. 2004; 32:127–135.
37. Corrigan, PW.; Roe, D.; Tsang, HWH. Challenging the stigma of mental illness: Lessons for therapists and advocates. Chichester, West Sussex: Wiley-Blackwell; 2011.
38. Hinshaw SP, Stier A. Stigma as related to mental disorders. *Annu Rev Clin Psycho*. 2008; 4:367–393.
39. Kessler, RC.; Ustun, TB. The WHO World Mental Health Surveys. Cambridge: Cambridge University Press; 2008.
40. Kessler RC, Ustun B. The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *Int J Meth Psychiat Res*. 2004; 13:93–121.
41. American Psychiatric Association. Diagnostic and statistical manual. Washington, DC: Author; 1994.
42. Kessler, RC.; Ustun, TB. The World Health Organization Composite International Diagnostic Interview. In: Kessler, RC.; Ustun, TB., editors. The WHO World Mental Health Surveys. New York: Cambridge University Press; 2006. p. 58-90.
43. Haro, JM.; Arbabzadeh-Bouchez, S.; Brugha, TS.; De Girolamo, G.; Guyer, ME.; Jin, R., et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. In: Kessler, RC.; Ustun, TB., editors. The WHO World Mental Health Surveys. New York: Cambridge University Press; 2006. p. 114-127.
44. Knight M, Stewart-Brown S, Fletcher L. Estimating health needs: The impact of a checklist of conditions and quality of life measurement on health information derived from community surveys. *J Public Health*. 2001; 23:179–186.
45. Fan VS, Au D, Heagerty P, Deyo RA, McDonnell MB, Fihn SD. Validation of case-mix measures derived from self-reports of diagnoses and health. *J Clin Epidemiol*. 2002; 55:371–380. [PubMed: 11927205]
46. National Center for Health Statistics. Evaluation of National Health Interview Survey diagnostic reporting. Vital and Health Statistics Series. 1994; 120:1–116.
47. Shah, BV. Linearization methods of variance estimation. In: Armitage, P.; Colton, T., editors. Encyclopedia of Biostatistics. Chichester: John Wiley and Sons; 1998. p. 2276-2279.
48. Institute, RT. SUDAAN: Software for the statistical analysis of correlated data [computer program]. Research Triangle Park, North Carolina, USA: 1999.

49. Spiegel D, Giese-Davis J. Depression and cancer: Mechanisms and disease progression. *Biol Psychiatry*. 2003; 54:269–282. [PubMed: 12893103]
50. Oerlemans ME, van der Akker N, Schuurman AG, Kellen E, Buntinx F. A meta-analysis on depression and subsequent cancer risk. *Clin Pract Epidemiol Ment Health*. 2007; 3:29–41.
51. Constanzo E, Ryff CD, Singer BH. Psychosocial adjustment among cancer survivors: Findings from a National Survey of Health and Well-Being. *Health Psychol*. 2009; 28:147–156. [PubMed: 19290706]
52. Meijer A, Roseman M, Milete K, Coyne JC, Stefanek ME, Ziegelstein RC, et al. Depression screening and patient putcomes in cancer: A systematic review. *PLoS ONE*. 2011; 6:e27181. [PubMed: 22110613]
53. World Health Organization. [Accessed November 22, 2012] Cancer morbidity and mortality. 2009. Available at http://www.who.int/gho/ncd/mortality_morbidity/cancer_text/en/index.html
54. Saraceno B, van Ommeren M, Batniji R, Cohen A, Gureje O, Mahoney J, et al. Barriers to improvement of mental health services in low-income and middle-income countries. *Lancet*. 2007; 370:1164–1174. [PubMed: 17804061]
55. Shim EJ, Mehnert A, Koyama A, Cho SJ, Inui H, Paik NS, et al. Health-related quality of life in breast cancer: A cross-cultural survey of German, Japanese, and South Korean patients. *Breast Cancer Res Tr*. 2006; 99:341–350.
56. Gordon LG, Beesley VL, Scuffham PA. Evidence on the economic value of psychosocial interventions to alleviate anxiety and depression among cancer survivors: A systematic review. *Asia Pac J Clin Oncol*. 2011; 7:96–105. [PubMed: 21585688]
57. Faller H, Bulzebruck H, Drings P, Lang H. Coping, distress, and survival among patients with lung cancer. *Arch Gen Psychiat*. 1999; 56:756. [PubMed: 10435611]
58. Hamer M, Chida Y, Molloy GJ. Psychological distress and cancer mortality. *J Psychosom Res*. 2009; 66(3):255–258. [PubMed: 19232239]
59. Spijker J, Nolen W. An algorithm for the pharmacological treatment of depression. *Acta Psychiat Scand*. 2010; 121:180–189. [PubMed: 19878134]
60. Jacobsen PB, Holland JC, Steensma DP. Caring for the Whole Patient: The Science of Psychosocial Care. *J Clin Oncol*. 2012; 30:1151–1153. [PubMed: 22412125]

Table 1
Respondents by sociodemographic characteristics, cancer status and other comorbid chronic conditions.

	Active cancer (n = 357)	Cancer survivors (n = 1373)	Cancer-free (n = 64657)	Test of difference χ^2	Test of difference [p]
Age (Mean, SE)	61.0	60.4	41.4	0.1	677.6* <0.0001
Gender (% female, SE)	57.4	3.7	63.7	1.8	51.6 0.3 24.4* <0.0001
Marital status (% SE)					
Married/Cohabiting	69.3	3.8	70.1	1.7	63.0 0.3 8.9* 0.0001
Previously married (Separated/Widowed/Divorced)	23.9	3.6	24.9	1.6	10.9 0.2 37.4* <0.0001
Never married	6.9	1.6	5.1	0.7	26.1 0.3 181.1* <0.0001
Education (% SE) ^a					
0–11 years education	27.7	3.6	25.9	1.7	17.6 0.2 14.1* <0.0001
12 years education	25.7	3.4	23.5	1.6	24.1 0.2 0.3 0.7288
13–15 years education	25.1	3.1	27.4	1.7	36.2 0.3 20.3* <0.0001
>= 16 years education	21.5	3.1	23.3	1.5	22.1 0.3 0.2 0.8639
Other chronic conditions (% SE) ^b	83.1	2.9	80.4	1.6	53.7 0.3 136.5* <0.0001

^aMissing education in France.

^bPercentage of respondents with 1 or more other chronic conditions: arthritis, back and neck pain, frequent or severe headaches, heart disease, high blood pressure, adult onset asthma, diabetes, peptic ulcer, other chronic lung diseases, stroke, other chronic pain, epilepsy and HIV.

Table 2

Respondents' cancer status by country.

Country	Sample size	Active cancer (unweighted number)	Weighted (%)	Cancer survivors (unweighted number)	Weighted (%)	Cancer-free (unweighted number)	Total number of respondents with cancer per country
High-income Countries							
Belgium	1043	4	0.29	37	3.13	1002	41
France	1436	8	0.41	45	3.66	1383	53
Germany	1323	11	0.80	45	3.13	1267	56
Israel	4859	47	0.85	132	2.58	4680	179
Italy	1779	9	0.45	40	2.15	1730	49
Japan	1682	9	0.35	49	2.57	1624	58
Netherlands	1094	5	0.91	45	2.65	1044	50
New Zealand	7312	75	0.99	323	4.93	6914	398
Northern Ireland	1986	10	0.47	34	1.90	1942	44
Poland	4000	27	0.47	47	0.93	3926	74
Portugal	2060	8	0.27	67	2.40	1985	75
Spain	2121	7	0.15	37	0.86	2077	44
US	5692	48	0.87	335	5.72	5309	383
Low-middle income Countries							
Brazil	2942	15	0.66	19	0.65	2908	34
Bulgaria	2233	11	0.32	19	0.55	2203	30
Colombia	2381	13	0.40	16	0.53	2352	29
Iraq	4332	7	0.16	3	0.13	4322	10
Lebanon	1031	1	0.16	1	0.12	1029	2
Mexico	2362	1	0.02	6	0.12	2355	7
Nigeria	2143	2	0.04	1	0.04	2140	3
Peru	1801	3	0.17	6	0.40	1792	9
PRC China (Beijing+Shanghai)	1628	3	0.09	3	0.06	1622	6
PRC Shenzhen	2475	1	0.01	6	0.14	2468	7
Romania	2357	12	0.43	16	0.57	2329	28
South Africa	4315	20	0.44	41	1.09	4254	61

Country	Sample size	Active cancer (unweighted number)	Weighted (%)	Cancer survivors (unweighted number)	Weighted (%)	Cancer-free (unweighted number)	Total number of respondents with cancer per country
Total	66387	357		1373		64657	1730

Table 3
Prevalence rates of 12-month mental disorders by respondents' cancer status and income-group countries.

	12-month mental disorders									
	Any mood ^a			Any anxiety ^b			Common mental disorders ^c			
	n	%	SE	n	%	SE	n	%	SE	SE
All countries										
Active cancer	48	9.3	1.5	79	14.9	1.9	96	18.4	2.1	2.1
Cancer survivors	152	5.9	0.6	292	12.2	0.8	355	14.6	0.9	0.9
Cancer-free	6019	5.3	0.1	10351	10.4	0.2	13566	13.3	0.2	0.2
High-income countries										
Active cancer	35	8.9	1.7	54	13.5	2.1	68	17.5	2.3	2.3
Cancer survivors	143	6.0	0.6	271	12.5	0.9	330	15.1	1.0	1.0
Cancer-free	3658	6.0	0.1	6348	11.1	0.2	8183	14.3	0.2	0.2
Low-middle income countries										
Active cancer	13	10.5	3.4	25	19.2	4.6	28	21.1	4.6	4.6
Cancer survivors	9	4.3	1.8	21	9.5	3.1	25	10.6	3.2	3.2
Cancer-free	2361	4.5	0.1	4003	9.5	0.2	5383	12.1	0.2	0.2

^a Respondents with any of the following 12-month mood disorder: Major depressive episode, Dysthymia and Bipolar disorders.

^b Respondents with any of the following 12-month anxiety disorder: Panic

^c Respondents with any 12-month mood disorder or 12-month anxiety disorder.

Table 4

Associations (odds ratios) between respondents' cancer status and 12-month mental disorders (all countries combined).

	12-month mental disorders		
	Any mood ^a	Any anxiety ^b	Common mental disorders ^c
	OR (95% C.I.)	OR (95% C.I.)	OR (95% C.I.)
1) Adjusted for age + gender + countries			
Active cancer	1.81* (1.26–2.61)	1.57* (1.14–2.17)	1.52* (1.13–2.05)
Cancer survivors	0.97 (0.78–1.21)	1.04 (0.88–1.22)	0.98 (0.84–1.14)
Cancer-free	1.00	1.00	1.00
2) Adjusted additionally for education and marital status			
Active cancer	1.81* (1.23–2.66)	1.58* (1.13–2.20)	1.53* (1.12–2.08)
Cancer survivors	0.97 (0.78–1.21)	1.04 (0.88–1.23)	0.98 (0.84–1.15)
Cancer-free	1.00	1.00	1.00
3) Adjusted additionally for other chronic physical conditions			
Active cancer	1.69* (1.15–2.48)	1.49* (1.07–2.09)	1.44* (1.05–1.97)
Cancer survivors	0.94 (0.75–1.17)	1.01 (0.86–1.19)	0.95 (0.82–1.11)
Cancer-free	1.00	1.00	1.00

* Significant at the .05 level, two-sided test.

^a Respondents with any of the following 12-month mood disorders: Major depressive episode, Dysthymia and Bipolar disorders.

^b Respondents with any of the following 12-month anxiety disorders: Panic disorder, Generalized anxiety disorder, Social phobia, Specific phobia, Agoraphobia without panic disorder, Post-traumatic stress disorder and Obsessive compulsive disorder.

^c Respondents with any 12-month mood disorder or 12-month anxiety disorder.

Table 5

Prevalence rates of 12-month service use among respondents with 12-month mental disorders by cancer status and country income level.

		Among respondents with 12-month mental disorders ^a											
		Number of respondents			Any treatment ^b			Mental health specialty ^c			General medical ^d		
		n	%	SE	n	%	SE	n	%	SE	n	%	SE
All countries													
Active cancer	357	0.5	0.0	53	59.0	5.3	25	29.9	5.4	37	37.9	6.0	7
Cancer survivors	1373	2.0	0.1	169	39.1	2.9	74	16.6	2.0	119	28.4	2.6	23
Cancer-free	64657	97.5	0.1	4694	27.7	0.5	2219	12.9	0.3	2903	17.0	0.4	579
Other chronic conditions	39291	54.3	0.3	3832	32.4	0.6	1760	14.7	0.4	2453	20.7	0.5	495
High income countries													
Active cancer	89	0.3	0.0	43	64.0	6.0	19	27.7	5.8	33	43.6	6.7	5
Cancer survivors	137	0.4	0.1	160	41.2	3.0	68	17.1	2.0	117	31.3	2.7	21
Cancer-free	29774	99.3	0.1	3520	35.6	0.6	1688	17.0	0.5	2340	23.5	0.5	425
Other chronic conditions	15685	46.8	0.4	2926	38.7	0.8	1359	18.0	0.6	1990	26.2	0.6	380
Low-middle income countries													
Active cancer	268	0.7	0.1	10	46.4	11.0	6	35.4	11.9	4	23.4	12.8	2
Cancer survivors	1236	3.3	0.1	9	22.5	9.1	6	12.7	7.0	2	4.7	4.2	2
Cancer-free	34883	96.1	0.1	1174	17.4	0.7	531	7.5	0.4	563	8.6	0.5	154
Other chronic conditions	23606	60.5	0.4	906	22.2	1.0	401	9.4	0.6	463	11.9	0.7	115

^aPercentages are based on respondents with any 12-month mental disorders.

^bRespondents who sought any form of professional treatments listed in the footnotes below.

^cThe mental health specialist sector, which includes psychiatrist and non-psychiatrist mental health specialists (psychiatrist, psychologist or other non-psychiatrist mental health professional; social worker or counsellor in a mental health specialty setting; use of a mental health helpline; or overnight admissions for a mental health or drug or alcohol problems, with a presumption of daily contact with a psychiatrist).

^dThe general medical sector (general practitioner, other medical doctor, nurse, occupational therapist or any healthcare professional).

^eThe human services sector (religious or spiritual advisor or social worker or counsellor in any setting other than a specialty mental health setting).

^fThe CAM (complementary and alternative medicine) sector (any other type of healer such as herbalist or homeopath, participation in an internet support group, or participation in a self-help group).